SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

CEO Angelos Stergious 15th-anniversary post highlighting GPS and SLS009 has fueled bullish interpretations and speculation about a potential buyout, though no deal is confirmed. The main debate centers on the REGAL Phase 3 trials final analysis: traders view the wait for the 80-event trigger as a possible sign of prolonged survival, while skeptics stress the uncertain, binary clinical outcome.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst is drawing attention for continued share-price weakness despite growing ORLADEYO sales and raised revenue guidance. Traders are divided between seeing the profitable business and pipeline as undervalued and doubting managements acquisition-led strategy, with sentiment hinging on future navenibart and Netherton data amid HAE competition.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows dominates discussion, with traders linking the weakness to deteriorating sentiment around Trump ahead of the midterms and the companys limited operating performance; bearish views prevail, though some see potential for a short-term bounce.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as Middle East conflict and reported attacks on shipping and energy infrastructure fuel concerns about oil supply disruptions. Traders are split between betting that those risks will keep oil elevated and expecting peace-deal headlines or a normalization of flows to unwind the risk premium, contributing to sharp swings.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriad Genetics agreement to sell its Prenatal Health testing business to Labcorp for cash is driving the sharp rally, with traders viewing the proceeds as a boost to liquidity and a chance to refocus on cancer diagnostics. Others question the sale of a major business, while much of the discussion centers on the surge, breakout levels and short-covering speculation; the transaction remains subject to closing conditions.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas planned public listing of its Monee financial-services arm and launch of an AI enterprise platform are driving the discussion as shares sell off. Traders worry that a separation could weaken the remaining business or take time to complete, while some view the listing as a way to unlock Monees value.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs steep selloff is being debated amid broader fears about neocloud financing and Gartners warning that many independent AI infrastructure providers could consolidate. Bullish traders point to CEO Daniel Roberts comments that IRENs data centers carry no debt and customer prepayments help fund GPU costs, while bears remain focused on weak price action and execution risks.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GEs strong third-quarter earnings beat and raised 2026 outlook have been overshadowed by a sharp share-price decline, with traders debating whether robust orders and services demand can outweigh weaker free cash flow, cost pressures, and an insurance-business loss. Some view the selloff as an overreaction to solid results, while others question margins and cash conversion.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTXs quarterly earnings beat, raised full-year outlook and record backlogsupported by long-term missile contracts and strong defense demandare driving attention. Traders welcome the results and demand outlook, but many are frustrated that the share price has stayed weak or turned red despite the positive news.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Unconfirmed Iran-U.S. deal chatter and a pullback in oil dominated discussion, with traders linking the headlines to a sharp QQQ rebound and volatile reversals. Bulls framed the move as a relief rally, while skeptics questioned the reports and warned of a bull trap; tech earnings and AI-sector weakness added uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate 

Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.

Should You Invest in the VanEck Biotech ETF (BBH)?

The Zacks Analyst Blog Highlights Amgen, Crinetics, FBT, BBH and BBP

Biotech ETFs are riding innovation, obesity drug growth and M&A, offering diversified exposure to the sector???s powerful rally.

Bet on These Biotech ETFs as Innovation Drives Market-Beating Growth 

 Biotech ETFs are riding a powerful rally fueled by innovation, obesity drugs and M&A, with three funds offering diversified exposure to growth.

Healthcare ETFs Are Looking Up: Here's Why 

Healthcare ETFs are hitting 52-week highs as earnings improve, dealmaking accelerates, FDA approvals stay strong and investors seek defensive growth.

Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

GILD Stock Jumps After Winning Accelerated FDA Approval For HDV Treatment 

Equity

 U.S. Food and Drug Administration (FDA) approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus.

The Zacks Analyst Blog Highlights IBB, XBI, BBH and GNOM

IBB and peers are gaining traction as AI transforms biotech, boosting drug discovery, trials and growth prospects across diversified ETF portfolios.

VanEck ETF Trust - VanEck Biotech ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Chronic HDV is considered the most severe form of viral hepatitis.</li><li>Bulevirtide 2 mg is also approved for use in the European Economic Area (EEA).&nbsp;</li><li>Gilead Sciences concluded the acquisition of Germany -based biotech firm Tubulis.</li></ul>Gilead Sciences (<a href="https://stocktwits.com/symbol/GILD">GILD</a>) share price gained nearly 3% on Friday and was set to record its best day in about three months after Federal regulators granted accelerated approval to Hepcludex, making it the first and only approved treatment in the U.S. for adults with chronic hepatitis delta virus infection.&nbsp;Chronic hepatitis delta, or HDV, only occurs as a co-infection in individuals who already carry the hepatitis B virus. It is associated with rapid progression to liver disease, liver failure, liver cancer and death. Health officials estimate that the disease affects between 40,000 and 80,000 Americans."Today's approval fills a critical gap in care for patients with chronic HDV infection, who until now have had no FDA-approved therapies available," said Dr. Wendy Carter, acting director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research.Hepcludex, known chemically as bulevirtide-gmod, acts as a first-in-class entry inhibitor, blocking both HDV and hepatitis B from entering liver cells and disrupting the viral lifecycle. It is administered via a once-daily injection for adults who either do not have cirrhosis or have compensated cirrhosis, a state where the liver is scarred but still functional.&nbsp;"The approval of Hepcludex represents a historic milestone for people living with HDV in the United States," said Dr. Dietmar Berger, chief medical officer at Gilead Sciences in a statement. "This reflects years of close engagement with the FDA and the application of rigorous science to address a serious disease with long-standing unmet need."&nbsp;In the U.S., HDV affects between 2% and 4% of individuals who have chronic hepatitis B virus (HBV), representing ~40,000-80,000 people, Gilead said in a release citing studies.&nbsp;<h2 class="st-heading-2">MYR301 study&nbsp;</h2>The FDA’s decision was heavily informed by data from a multi-center Phase 3 clinical trial, known as MYR301.Participants were randomly assigned to immediate treatment with Hepcludex 8.5 mg once daily for 144 weeks or to delayed treatment with an observational period of 48 weeks followed by Hepcludex 8.5 mg once daily for 96 weeks.Furthermore, data showed that the percentage of participants with completely undetectable viral levels climbed steadily from 20% at week 48 to 50% by week 144.The FDA previously granted Hepcludex breakthrough therapy and orphan-drug designations to expedite its review. While newly approved in the U.S., a 2 mg dose of the drug has already been available in the European Economic Area and other global markets.&nbsp;<h2 class="st-heading-2">GILD Retail View&nbsp;</h2>Retail sentiment on Stocktwits was ‘normal’ with ‘high’ message volumes.&nbsp;The stock has gained 29% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Gilead Sciences logo is displayed on a smartphone screen, with the company's branding visible in the background, on April 20, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Gilead Sciences (GILD) share price gained nearly 3% on Friday and was set to record its best day in about three months after Federal regulators granted accelerated approval to Hepcludex, making it the first and only approved treatment in the U.S. for adul

VanEck Biotech ETF

Gilead Sciences, Inc.

iShares Biotechnology ETF

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$247.29
Prev Close	$241.14
Open	$241.86
Dividend Yield	N/A
50-Day Moving Average	$236.34
Beta	N/A
Avg. Volume	12,475.08
PE Ratio	N/A

52-Week High	$247.90
52-Week Low	$176.30
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

BBH Fundamentals